Evidence map›Paper›PMID 34202765›Full record

ArticleMaterials (Basel, Switzerland)2021

Cartilage Tissue Engineering by Extrusion Bioprinting: Process Analysis, Risk Evaluation, and Mitigation Strategies.

Mauro Petretta, Giovanna Desando, Brunella Grigolo, Livia Roseti

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mauro PetrettaRegenHU Ltd., Z.I. du Vivier 22, 1690 Villaz-ST-Pierre, Switzerland.ORCID 0000-0002-8803-7013
Giovanna DesandoRizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.ORCID 0000-0003-3338-5747
Brunella GrigoloRizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.ORCID 0000-0002-3990-6745
Livia RosetiRizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.ORCID 0000-0001-5760-3791
Istituto Ortopedico Rizzoli · IT

Funding

Italian Ministry of Health, 5x1000 funds, anno 2017, redditi 2106, "Sviluppo di un device stampato in 3D per l'inserzione tibiale del legamento crociato anteriore"
6 · The paper itself

Abstract

Extrusion bioprinting is considered promising in cartilage tissue engineering since it allows the fabrication of complex, customized, and living constructs potentially suitable for clinical applications. However, clinical translation is often complicated by the variability and unknown/unsolved issues related to this technology. The aim of this study was to perform a risk analysis on a research process, consisting in the bioprinting of a stem cell-laden collagen bioink to fabricate constructs with cartilage-like properties. The method utilized was the Failure Mode and Effect Analysis/Failure Mode and Effect Criticality Analysis (FMEA/FMECA) which foresees a mapping of the process to proactively identify related risks and the mitigation actions. This proactive risk analysis allowed the identification of forty-seven possible failure modes, deriving from seventy-one potential causes. Twenty-four failure modes displayed a high-risk level according to the selected evaluation criteria and threshold (RPN > 100). The results highlighted that the main process risks are a relatively low fidelity of the fabricated structures, unsuitable parameters/material properties, the death of encapsulated cells due to the shear stress generated along the nozzle by mechanical extrusion, and possible biological contamination phenomena. The main mitigation actions involved personnel training and the implementation of dedicated procedures, system calibration, printing conditions check, and, most importantly, a thorough knowledge of selected biomaterial and cell properties that could be built either through the provided data/scientific literature or their preliminary assessment through dedicated experimental optimization phase. To conclude, highlighting issues in the early research phase and putting in place all the required actions to mitigate risks will make easier to develop a standardized process to be quickly translated to clinical use.

Indexed as

bioprintingcartilage regenerationFMEA/FMECAtranslational research

Identifiers

PMID34202765
PMCPMC8269498
OpenAlexW3176203329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.